Array
(
[1585396412] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1585397282] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1585397552] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585399173] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1585399681] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1585399718] => Array
(
[w3_pgcache_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => w3_pgcache_cleanup
[args] => Array
(
)
[interval] => 3600
)
)
)
[1585402326] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1585403074] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585408673] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1585411624] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585414611] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585465712] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585471771] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585476911] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585476952] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1585538951] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1585576199] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[4e1511def1628897bdbbaaa0d8beffd0] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1585576199
)
)
)
)
[1585835399] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[70db2f7ed5dc83dbda98262ab50954d0] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1585835399
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: Actualización 2014, ALO‐TPH, Álvaro Urbano, Ana Villegas, Beatriz Arrizabalaga, Consenso español, Criterios de continuación, Diagnóstico, Eculizumab, Enrique Colado, Guía clínica HPN, Hemoglobinuria Paroxística Nocturna, Hipertensión pulmonar, HPN, insuficiencia renal crónica, Madrid, pacientes, Recogida de datos, Registro Nacional e Internacional, salud, Sanidad, Seguimiento, SEHH, Sociedad Española de Hematología y Hemoterapia, Tratamiento.
Etiquetas: 2007, Abatacept, Actividad, Atomoxetina, Eculizumab, Efecto, EMEA, Enero 2008, Epoetina Delta, Grupo A.T.C, Iobenguano, Ivabrandina, Lenalidomida, Madrid, Maraviroc, Mecasermina, Medicamentos huérfanos, Nelarabina, Nuevos, Papiloma humano virus, Perflutren, Presentación, principios activos, Ranibizumad, Retapamulina, Revisión, salud, Sanidad, Sistema Nacional de Salud, Sitagliptina, Tabla, Trabectedina, Volumen 32, Ziconotida.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)